UNSPSC 51293701: Diclofensine

This classification denotes an antidepressant agent with the molecular formula C17H17CL2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 09HKW863J6 chemically known as (+/-)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline but generally known as diclofensine, which bears US NIH Compound Identifier 68871. European Medicines Agency schedules Diclofensine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07094MIG.

UNSPSC 51293701 Diclofensine is a Commodity code that nominally covers a specific pharmaceutical product, but recent state and local opportunities tagged under this code actually reflect broader pharmaceutical and health-supply procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local issuing bodies in this space include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves sourcing and delivering pharmaceutical products and medical supplies to support community health initiatives, emergency response capabilities, and managed healthcare programs across participating state and local facilities.

Recent activity shows geographic concentration in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; vendors must cover shipping and delivery costs and comply with E-Verify and drug-free workplace requirements. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements, seeking information on vendor experience with direct contracting and value-based pricing models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awarded vendor lists provided to wholesalers by May 15, 2026 and contracts effective July 1, 2026; vendors must maintain cGMP and DSCSA compliance, hold relationships with at least two of three specified wholesalers, and carry $5 million commercial general liability coverage.